There are currently 36 clinical trials in Clermont, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including South Lake Pain Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
NCT05443724
Recruiting
The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/12/2024
Locations: Clermont, Florida, Clermont, Florida
Conditions: Schizophrenia
Register for Updates
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
NCT03464097
Recruiting
This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/06/2024
Locations: South Lake Pain Institute, Clermont, Florida
Conditions: Crohn Disease
Register for Updates
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT06094296
Recruiting
The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in combination with PDCT in the first-line treatment of Stage IV or recurrent non-small cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: Clermont Oncology Center, Clermont, Florida
Conditions: NSCLC
Register for Updates
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
02/06/2024
Locations: Site 159, Clermont, Florida
Conditions: Major Depressive Disorder
Register for Updates
Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)
NCT05593614
Recruiting
The purpose of this clinical trial is to compare the efficacy of twice daily applications of ATX01 (10% & 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivor patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: South Lake Pain Institute, Clermont, Florida
Conditions: Chemotherapy-induced Peripheral Neuropathy
Register for Updates
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05850689
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/09/2024
Locations: Clinical Site, Clermont, Florida
Conditions: Major Depressive Disorder
Register for Updates
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
NCT05060432
Recruiting
This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Clermont Oncology Center, Clermont, Florida
Conditions: Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
Register for Updates
Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery
NCT04967664
Recruiting
This is an interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated topical application of Qutenza (capsaicin 8% topical system) versus low-dose capsaicin control (capsaicin 0.04% topical system) in subjects with moderate to severe postsurgical neuropathic pain (PSNP).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: South Lake Pain Institute, Clermont, Florida
Conditions: Post Surgical Neuropathic Pain
Register for Updates
Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis
NCT05177107
Recruiting
This is a phase IIa randomized trial designed to evaluate bacteriophage therapy in patients with diabetic foot osteomyelitis.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
09/05/2023
Locations: South Lake Pain Institute, Clermont, Florida
Conditions: Osteomyelitis, Diabetic Foot Osteomyelitis
Register for Updates
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
NCT05686239
Recruiting
The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer are: Does RL-007 improve subjects performance in a set of cognitive tasks? Which dose of RL-007 (20 mg or 40 mg) has a larger effect on cognitive performance? How well do subjects tolerate RL-007? In the study, subjects will perform the cognitive tasks at the beginning to get familiar with the tasks... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
08/23/2023
Locations: Recognify Research Site, Clermont, Florida
Conditions: Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
Register for Updates
AngelMed Guardian® System PMA Post Approval Study
NCT05412927
Recruiting
500 Patients (minimum) will be enrolled following commercial implant. Will be treated by their physicians using the standard of care. Standard of care for the Guardian includes an in-office initial programming visit 7-14 days following implant and every 6 months.
Gender:
All
Ages:
21 years and above
Trial Updated:
08/18/2023
Locations: Clermont Ambulatory Surgical Center, Clermont, Florida
Conditions: Acute Coronary Syndrome
Register for Updates
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
NCT05577715
Recruiting
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/17/2023
Locations: Clermont Oncology Center, Clermont, Florida
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates